[Federal Register Volume 75, Number 198 (Thursday, October 14, 2010)]
[Notices]
[Page 63203]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-25849]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 28, 2010, PCAS-
Nanosyn, LLC, 3331-B Industrial Drive, Santa Rosa, California 95403, 
made application to the Drug Enforcement Administration (DEA) as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Phencyclidine (7471).......................  II
Codeine (9050).............................  II
Diprenorphine (9058).......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Oxymorphone (9652).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of controlled 
substances in bulk form only. The primary service provided by the 
company to its customers is the development of the process of 
manufacturing the derivative. As part of its service to its customers, 
the company distributes the derivatives of the controlled substances it 
manufactures to those customers. The company's customers use the newly-
created processes and the manufactured derivatives in furtherance of 
formulation processes and dosage form manufacturing; pre-clinical 
studies, including toxicological studies; clinical studies supporting 
investigational Drug Applications; and use in stability studies.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR Sec.  1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than December 13, 2010.

    Dated: October 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-25849 Filed 10-13-10; 8:45 am]
BILLING CODE 4410-09-P